Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
NCT ID: NCT03207256
Last Updated: 2022-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
51 participants
INTERVENTIONAL
2017-08-09
2022-06-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
NCT02656303
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
NCT03828448
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT04806035
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
NCT02006485
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
NCT04149821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TGR-1202
Oral TGR-1202 Daily
TGR-1202
Oral Daily TGR-1202
TGR-1202 + Ublituximab
Oral TGR-1202 in combination with Ublituximab intravenous administration
TGR-1202 + Ublituximab
Oral Daily TGR-1202 + Ublituximab IV Administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TGR-1202
Oral Daily TGR-1202
TGR-1202 + Ublituximab
Oral Daily TGR-1202 + Ublituximab IV Administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have completed at least 6 cycles of therapy on their current protocol.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TG Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TG Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
TG Therapeutics Investigational Trial Site
Tucson, Arizona, United States
TG Therapeutics Investigational Trial Site
Fayetteville, Arkansas, United States
TG Therapeutics Investigational Trial Site
Duarte, California, United States
TG Therapeutics Investigational Trial Site
Fort Myers, Florida, United States
TG Therapeutics Investigational Trial Site
Atlanta, Georgia, United States
TG Therapeutics Investigational Trial Site
Fort Wayne, Indiana, United States
TG Therapeutics Investigational Trial Site
Coon Rapids, Minnesota, United States
TG Therapeutics Investigational Trial Site
Omaha, Nebraska, United States
TG Therapeutics Investigational Trial Site
Durham, North Carolina, United States
TG Therapeutics Investigational Site
Canton, Ohio, United States
TG Therapeutics Investigational Trial Site
Cincinnati, Ohio, United States
TG Therapeutics Investigational Trial Site
Nashville, Tennessee, United States
TG Therapeutics Investigational Trial Site
Denton, Texas, United States
TG Therapeutics Investigational Trial Site
San Antonio, Texas, United States
TG Therapeutics Investigational Trial Site
Seattle, Washington, United States
TG Therapeutics Investigational Trial Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UTX-TGR-501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.